근거중심한의약 DB
Home > 한의약융합데이터센터 > 근거중심한의약 DB| Title | Ω 3 fatty acids may reduce hyperlipidemia in pediatric renal transplant recipients. |
|---|---|
| Authors | Filler G, Weiglein G, Gharib MT, Casier S. |
| Journal | Pediatr Transplant. |
| Year | 2012 |
| Vol (Issue) | 16(8) |
| Page | 835-9. |
| doi | 10.1111/j.1399-3046.2012.01772.x. |
| PMID | |
| Url | |
| MeSH | Adolescent |
| Keywords | cholesterol; triglycerides; docosahexaenoic acid; eicosapentaenoic acid; sirolimus |
| 한글 키워드 | 콜레스테롤; 트리글리세라이드; 도코사헥사엔산; 에이코사펜타엔산; 시롤리무스 |
| KMCRIC summary and commentary | 없음 |
| Korean Study | |
| Abstract | Life expectancy after pediatric renal transplantation remains lower than that of the normal population largely due to cardiovascular morbidity and mortality. Hyperlipidemia is a potentially modifiable risk factor for cardiovascular morbidity. Retrospective chart review of all available pediatric renal transplant patients (26) in a single center with assessment of anthropometry, renal function, steroid, calcineurin or mTOR inhibitor exposure and Ω3 FA supplementation. Eighteen transplant recipients without Ω3 FA supplementation served as control. Nutrition and supplement surveys were conducted with standardized questionnaires. Fasting cholesterol values were compared using the latest value prior to start of Ω3 FA and at last follow-up. Eight patients (five receiving mTOR inhibitor) started Ω3 FA supplementation at a mean dose of 29.2 ± 12 mg of EPA/kg and 16.1 ± 7.4 mg DHA/kg body weight. Median duration of treatment was 2.5 yr (range 0.8-5.9 yr) and their total fasting cholesterol at last follow-up dropped significantly from 5.08 ± 0.97 (control group 3.77 ± 0.81, p = 0.0084) to 4.17 ± 0.54 mm (p = 0.0158). High-density lipoprotein cholesterol increased not significantly from 1.74 ± 0.49 to 2.02 ± 0.93 mm. No patient had increased bleeding. Supplementation of omega-3 FAs may reduce hyperlipidaemia after pediatric renal transplantation. |
| 국문초록 | |
| Language | 영어 |
| 첨부파일 |












